Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors

被引：0

作者：

Noritoshi, K. ^{[1
]}

Sho, H. ^{[1
]}

Wild, D. ^{[2
]}

Kaul, F. ^{[2
]}

Motokazu, S. ^{[1
]}

Naoki, O. ^{[1
]}

Risa, F. ^{[1
]}

Akihiro, S. ^{[1
]}

Motohiko, T. ^{[1
]}

Shoko, T. ^{[1
]}

Yasushi, I ^{[1
]}

机构：

[1] Yokohama City Univ, Yokohama, Kanagawa, Japan

[2] Univ Hosp Basel, Basel, Switzerland

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷

关键词：

lesion-based analysis; neuroendocrine tumor; peptide receptor radionuclide therapy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H29

引用

页码：201 / 201

页数：1

共 50 条

[31] Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy [J].

Mathew, Annie ;

Kersting, David ;

Fendler, Wolfgang P. ;

Braegelmann, Johanna ;

Fuhrer, Dagmar ;

Lahner, Harald .

FRONTIERS IN ENDOCRINOLOGY, 2025, 16

[32] Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging [J].

Paolo Zanotti-Fregonara ;

Clément Morgat ;

Christophe Champion ;

Elif Hindié .

European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 :1095-1096

[33] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients [J].

Becx, Morticia N. ;

Minczeles, Noemie S. ;

Brabander, Tessa ;

de Herder, Wouter W. ;

Nonnekens, Julie ;

Hofland, Johannes .

CANCERS, 2022, 14 (23)

[34] The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis [J].

Dannoon, Shorouk F. ;

Alenezi, Saud A. ;

Elgazzar, Abdelhamid H. .

NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (12) :1085-1093

[35] Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors [J].

Kim K. ;

Kim S.-J. .

Nuclear Medicine and Molecular Imaging, 2018, 52 (3) :208-215

[36] Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience [J].

Grewal, Udhayvir S. ;

Loeffler, Bradley T. ;

Paschke, Alexander ;

Dillon, Joseph S. ;

Chandrasekharan, Chandrikha .

JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (03) :1165-1170

[37] Intense 18F-Fluoride Accumulation in Liver Metastases From a Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy [J].

Swietaszczyk, Cyprian ;

Prasad, Vikas ;

Baum, Richard P. .

CLINICAL NUCLEAR MEDICINE, 2012, 37 (04) :E82-E83

[38] Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy [J].

Rabei, Rana ;

Fidelman, Nicholas .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) :1994-2004

[39] Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy [J].

Rana Rabei ;

Nicholas Fidelman .

Current Treatment Options in Oncology, 2023, 24 :1994-2004

[40] Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors [J].

Alsadik, S. R. ;

Gnanasegaran, G. ;

Chen, L. ;

Toumpanakis, C. ;

Caplin, M. ;

Navalkissoor, S. .

JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :172-172

← 1 2 3 4 5 →